Breast Cancer News and Research

Latest Breast Cancer News and Research

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Cardinal Bank announced today that the Cardinal Bank Community Fund has awarded $5,000 to the Prevent Cancer Foundation. The mission of the Alexandria-based organization is to save lives through cancer prevention and early detection, and it has provided more than $130 million to support cancer prevention, early detection research, education, advocacy, and community outreach nationwide.

18 Dec 2013

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, Distinguished Scientist with Berkeley Lab's Life Sciences Division and a leading authority on breast cancer, has shown that aerobic glycolysis - glucose metabolism in the presence of oxygen - is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.

18 Dec 2013

Scientists back ovarian cancer preventative surgery to improve survival

A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because of genetic faults.

18 Dec 2013

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Scientists from UCLA are now bringing their groundbreaking stem cell science directly to patients in two exciting new clinical trials scheduled to begin in early 2014, thanks to funding from California's stem cell agency.

17 Dec 2013

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

New report shows death rates for lung cancer dropping at a faster pace

The Annual Report to the Nation on the Status of Cancer, covering the period 1975, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends. The lung cancer death rate decline, as well as declines in colorectal, breast, and prostate cancer death rates, has also helped drive decreases in death rates for all cancers types combined, a trend that began about 20 years ago.

17 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Breast cancer patients are moms, wives, and caretakers. They are teachers, nurses, physicians and heads of industry. Today, more than ever before, women are delicately balancing the various roles of their lives. A breast cancer diagnosis and the treatment that follows is yet another challenge that unfortunately many women need to accommodate in their already busy schedules. That's why Jersey Shore University Medical Center, Ocean Medical Center and Riverview Medical Center offer technologies that provide expert care and streamline the process of treating breast cancer.

14 Dec 2013

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

13 Dec 2013

Anastrozole drug reduces breast cancer in high risk post-menopausal women

Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study published in the Lancet today.

13 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

Breast Cancer News and Research

Latest Breast Cancer News and Research

Alexandria-based Prevent Cancer Foundation gets $5,000 grant from Cardinal Bank Community

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Scientists back ovarian cancer preventative surgery to improve survival

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

New report shows death rates for lung cancer dropping at a faster pace

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Study could lead towards a personalised medicine for chemoresistant lymphomata

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Researchers test promising new breast cancer drugs

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

Anastrozole drug reduces breast cancer in high risk post-menopausal women

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Industry Focus eBook - Oncology (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in